

# Aik-Choon Tan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8596381/aik-choon-tan-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213 papers	9,613 citations	51 h-index	91 g-index
260 ext. papers	11,518 ext. citations	7.6 avg, IF	5.89 L-index

#	Paper	IF	Citations
213	Patient-derived tumour xenografts as models for oncology drug development. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 338-50	19.4	900
212	Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. <i>Nature Medicine</i> , <b>2011</b> , 17, 860-6	50.5	553
211	Simple decision rules for classifying human cancers from gene expression profiles. <i>Bioinformatics</i> , <b>2005</b> , 21, 3896-904	7.2	287
210	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5581-90	12.9	284
209	A DNA methylation fingerprint of 1628 human samples. <i>Genome Research</i> , <b>2012</b> , 22, 407-19	9.7	273
208	Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. <i>Nature Medicine</i> , <b>2011</b> , 17, 1109-15	50.5	256
207	The miR-106b-25 cluster targets Smad7, activates TGF- $\beta$ signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. <i>Oncogene</i> , <b>2012</b> , 31, 5162-71	9.2	246
206	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3059-3068	12.9	211
205	A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. <i>Oncogenesis</i> , <b>2013</b> , 2, e39	6.6	179
204	Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5793-800	12.9	175
203	Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. <i>Cell Research</i> , <b>2012</b> , 22, 321-32	24.7	143
202	Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. <i>Journal of Parkinsons Disease</i> , <b>2012</b> , 2, 321-31	5.3	132
201	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3299-309	12.9	127
200	DSigDB: drug signatures database for gene set analysis. <i>Bioinformatics</i> , <b>2015</b> , 31, 3069-71	7.2	123
199	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5368-5380	12.9	120
198	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , <b>2018</b> , 23, 86-100.e6	18	116
197	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. <i>Molecular Oncology</i> , <b>2013</b> , 7, 776-90	7.9	116

196	Characterizing DNA methylation patterns in pancreatic cancer genome. <i>Molecular Oncology</i> , <b>2009</b> , 3, 425-38	7.9	115
195	Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. <i>Bioinformatics</i> , <b>2005</b> , 21, 3905-11	7.2	108
194	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. <i>Cancer Research</i> , <b>2012</b> , 72, 4154-64	10.1	105
193	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2257-67	15.9	105
192	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1710-1721	12.9	101
191	A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2013-24	4.6	96
190	XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. <i>Oncogene</i> , <b>2016</b> , 35, 290-300	9.2	94
189	Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4666-80	15.9	90
188	Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. <i>Melanoma Research</i> , <b>2017</b> , 27, 189-199	3.3	86
187	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e82236	3.7	85
186	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 2841-9	10.1	84
185	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2742-7	11.5	80
184	Systems biology approaches for advancing the discovery of effective drug combinations. <i>Journal of Cheminformatics</i> , <b>2015</b> , 7, 7	8.6	79
183	Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4138-46	12.9	76
182	Collagen architecture in pregnancy-induced protection from breast cancer. <i>Journal of Cell Science</i> , <b>2013</b> , 126, 4108-10	5.3	72
181	Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	70
180	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3275-84	6.1	70
179	Merging microarray data from separate breast cancer studies provides a robust prognostic test. <i>BMC Bioinformatics</i> , <b>2008</b> , 9, 125	3.6	69

178	Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 62	42.1	67
177	Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 3351-62	6.1	66
176	Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3193-204	12.9	65
175	Brusatol overcomes chemoresistance through inhibition of protein translation. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 1493-1500	5	64
174	CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. <i>Cancer Research</i> , <b>2018</b> , 78, 6561-6574	10.1	64
173	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4356-64	12.9	62
172	Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , <b>2012</b> , 26, 1266-76	10.7	61
171	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 649-55	8.7	61
170	Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4149-62	12.9	58
169	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. <i>Nature Chemical Biology</i> , <b>2012</b> , 8, 646-54	11.7	57
168	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , <b>2016</b> , 55, 2220-2229	3.9	56
167	GSEA-InContext: identifying novel and common patterns in expression experiments. <i>Bioinformatics</i> , <b>2018</b> , 34, i555-i564	7.2	54
166	BEST: Next-Generation Biomedical Entity Search Tool for Knowledge Discovery from Biomedical Literature. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164680	3.7	54
165	Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. <i>Molecular and Cellular Proteomics</i> , <b>2009</b> , 8, 1765-76	7.6	53
164	ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E6669-E6678	11.5	52
163	DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. <i>International Journal of Medical Sciences</i> , <b>2013</b> , 10, 1727-39	3.7	51
162	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2314-2322	6.1	51
161	Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3141-3151	12.9	50

160	RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis. <i>EMBO Reports</i> , <b>2015</b> , 16, 700-8	6.5	49
159	Twist1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. <i>Cancer Research</i> , <b>2015</b> , 75, 1908-21	10.1	48
158	The mutational landscape of mucosal melanoma. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 61, 139-148	12.7	46
157	Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. <i>Cancer Research</i> , <b>2015</b> , 75, 4398-406	10.1	45
156	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. <i>BMC Genomics</i> , <b>2017</b> , 18, 934	4.5	45
155	A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. <i>Cell Reports</i> , <b>2013</b> , 3, 1346-54	10.6	45
154	Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6219-29	12.9	45
153	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1623-1633	6.1	44
152	Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2013</b> , 122, 1599-609	2.2	43
151	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1656-65	12.9	43
150	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1441-56	9.7	41
149	Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 6490-501	10.1	41
148	Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 15105-15120	5.4	40
147	Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2017</b> , 76, 779-788	3.1	39
146	Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4949-4959	12.9	39
145	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1531-1541	12.9	38
144	Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2704-14	12.9	38
143	Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4165-77	12.9	37

142	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1484-93	6.1	37
141	Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 135-44	4.6	37
140	Dual Targeting of PDGFR $\alpha$ and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. <i>Cell Reports</i> , <b>2016</b> , 17, 1265-1275	10.6	36
139	A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. <i>Molecular Pharmacology</i> , <b>2013</b> , 83, 882-93	4.3	36
138	Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1051-62	12.9	36
137	Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1967-75	7.5	35
136	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 291-303	12.9	34
135	IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2016</b> , 23, 721-30	8.6	34
134	The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. <i>Nature Communications</i> , <b>2015</b> , 6, 10077	17.4	33
133	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e113037	3.7	33
132	Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. <i>Cancer Research</i> , <b>2014</b> , 74, 7357-70	10.1	33
131	The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5436-46	12.9	33
130	Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. <i>Oncotarget</i> , <b>2016</b> , 7, 27802-18	3.3	33
129	Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. <i>Hormones and Cancer</i> , <b>2013</b> , 4, 140-53	5	30
128	Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a $\beta$ -secretase inhibitor, in a preclinical colorectal explant model. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 667-75	8.7	30
127	MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 753-7	4.5	30
126	Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	30
125	Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 30-41	6.6	30



124	Kinase gene fusions in defined subsets of melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2017</b> , 30, 53-62	4.5	29
123	Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. <i>Oncogene</i> , <b>2010</b> , 29, 6603-62	3.2	29
122	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1117-29	6.1	28
121	Deep learning of mutation-gene-drug relations from the literature. <i>BMC Bioinformatics</i> , <b>2018</b> , 19, 21	3.6	28
120	ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a secretase inhibitor and irinotecan in colorectal cancer. <i>Molecular Oncology</i> , <b>2012</b> , 6, 370-81	7.9	28
119	Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins. <i>Cell Reports</i> , <b>2015</b> , 11, 1727-36	10.6	27
118	Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 317-25	6.1	27
117	Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	26
116	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. <i>Frontiers in Pharmacology</i> , <b>2013</b> , 4, 22	5.6	26
115	Multi-class protein fold classification using a new ensemble machine learning approach. <i>Genome Informatics</i> , <b>2003</b> , 14, 206-17		26
114	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. <i>Frontiers in Pharmacology</i> , <b>2013</b> , 4, 35	5.6	25
113	Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. <i>Oncotarget</i> , <b>2016</b> , 7, 51619-51625	3.3	25
112	ALK Inhibitor Response in Melanomas Expressing Fusions and Alternate Isoforms. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 222-231	6.1	24
111	BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. <i>Methods in Molecular Biology</i> , <b>2012</b> , 802, 389-98	1.4	24
110	A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 195-205	7.5	24
109	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1474-1485	12.9	24
108	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 443	9.8	23
107	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2257-2265	6.1	23

106	Long term storage of dry versus frozen RNA for next generation molecular studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e111827	3.7	23
105	A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. <i>International Journal of Genomics</i> , <b>2016</b> , 2016, 7983236	2.5	23
104	Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. <i>Nature Communications</i> , <b>2020</b> , 11, 2393	17.4	22
103	A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2016</b> , 53, 74-9	4.4	22
102	The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1994-2005	6.1	22
101	BRONCO: Biomedical entity Relation ONcology CORpus for extracting gene-variant-disease-drug relations. <i>Database: the Journal of Biological Databases and Curation</i> , <b>2016</b> , 2016,	5	22
100	Exploiting receptor tyrosine kinase co-activation for cancer therapy. <i>Drug Discovery Today</i> , <b>2017</b> , 22, 72-84	8.8	21
99	A survey of statistical software for analysing RNA-seq data. <i>Human Genomics</i> , <b>2010</b> , 5, 56-60	6.8	21
98	The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. <i>Oncotarget</i> , <b>2018</b> , 9, 33110-33123	3.3	21
97	K-Map: connecting kinases with therapeutics for drug repurposing and development. <i>Human Genomics</i> , <b>2013</b> , 7, 20	6.8	20
96	Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. <i>Proteomics - Clinical Applications</i> , <b>2009</b> , 3, 1288-95	3.1	20
95	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. <i>Science Signaling</i> , <b>2016</b> , 9, rs12	8.8	19
94	Mammary epithelial cell phagocytosis downstream of TGF- $\beta$ is characterized by adherens junction reorganization. <i>Cell Death and Differentiation</i> , <b>2016</b> , 23, 185-96	12.7	19
93	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 50290-50301	3.3	19
92	Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 62939-62953	3.3	19
91	ReSimNet: drug response similarity prediction using Siamese neural networks. <i>Bioinformatics</i> , <b>2019</b> , 35, 5249-5256	7.2	18
90	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment- naïve Lesions. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1496-1507	8.9	18
89	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 971-991	3.5	18



88	Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. <i>Bioinformatics</i> , <b>2014</b> , 30, 2393-8	7.2	18
87	Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. <i>Oncogenesis</i> , <b>2017</b> , 6, e287	6.6	16
86	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 94	5.3	16
85	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 120	5.6	16
84	IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , <b>2019</b> , 42, 477-490	7.2	15
83	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2935-2943	12.9	15
82	Contrasting roles for C/EBP $\beta$ and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects. <i>Stem Cells</i> , <b>2015</b> , 33, 1345-58	5.8	15
81	A short survey of computational analysis methods in analysing ChIP-seq data. <i>Human Genomics</i> , <b>2011</b> , 5, 117-23	6.8	15
80	Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene expression signatures and connectivity map. <i>Computer Methods and Programs in Biomedicine</i> , <b>2019</b> , 174, 33-40	6.9	15
79	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 8823-8835	13.8	15
78	Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187173	3.7	14
77	The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1952-63	6.1	14
76	Multomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , <b>2020</b> , 21, 271	18.3	13
75	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). <i>Investigational New Drugs</i> , <b>2017</b> , 35, 11-25	4.3	12
74	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. <i>Cancer Medicine</i> , <b>2012</b> , 1, 207-17	4.8	12
73	HiPub: translating PubMed and PMC texts to networks for knowledge discovery. <i>Bioinformatics</i> , <b>2016</b> , 32, 2886-8	7.2	12
72	Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. <i>Nature Ecology and Evolution</i> , <b>2021</b> , 5, 379-391	12.3	12
71	PKC $\zeta$ regulates integrin $\alpha$ $\beta$ expression and transformed growth of K-ras dependent lung cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 17905-19	3.3	11

70	Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. <i>Oncogene</i> , <b>2019</b> , 38, 2565-2579	9.2	11
69	Co-dependency of PKC $\delta$ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. <i>Oncogene</i> , <b>2017</b> , 36, 4370-4378	9.2	10
68	Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. <i>Chemico-Biological Interactions</i> , <b>2019</b> , 314, 108822	5	10
67	PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, D668-D676	20.1	10
66	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	10
65	Host response transcriptional profiling reveals extracellular components and ABC (ATP-binding cassette) transporters gene enrichment in typhoid fever-infected Nigerian children. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 241	4	10
64	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. <i>Oncotarget</i> , <b>2015</b> , 6, 34561-72	3.3	10
63	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits E-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1916-1925	6.1	9
62	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1598-1612	6.1	9
61	Automatic context-specific subnetwork discovery from large interaction networks. <i>PLoS ONE</i> , <b>2014</b> , 9, e84227	3.7	9
60	Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. <i>ELife</i> , <b>2020</b> , 9,	8.9	9
59	Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. <i>Bioinformatics</i> , <b>2015</b> , 31, 3799-806	7.2	8
58	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
57	A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 382-394	6.6	7
56	Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials. <i>Assay and Drug Development Technologies</i> , <b>2016</b> , 14, 557-566	2.1	7
55	Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. <i>Cancer Research</i> , <b>2020</b> , 80, 1183-1198	10.1	7
54	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 136	4.8	6
53	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. <i>BMC Genomics</i> , <b>2015</b> , 16 Suppl 12, S2	4.5	6

52	Novel agents in the treatment of metastatic colorectal cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 273-82	2.2	6
51	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , <b>2021</b> , 15, 195-209	7.9	6
50	Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association Studies with Traditional Chinese Medicine. <i>International Journal of Genomics</i> , <b>2018</b> , 2018, 7697356	2.5	6
49	GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. <i>Journal of Dental Research</i> , <b>2018</b> , 97, 909-916	8.1	5
48	A Pilot Study of Biomedical Text Comprehension using an Attention-Based Deep Neural Reader: Design and Experimental Analysis. <i>JMIR Medical Informatics</i> , <b>2018</b> , 6, e2	3.6	5
47	Loss of prdm1a accelerates melanoma onset and progression. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 1052-1063	3.063	4
46	BEReX: Biomedical Entity-Relationship eXplorer. <i>Bioinformatics</i> , <b>2014</b> , 30, 135-6	7.2	4
45	An Inducible TGF- $\beta$ -TGFR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123600	3.7	4
44	<b>2008</b> ,		4
43	MSAT: a multiple sequence alignment tool based on TOPS. <i>Applied Bioinformatics</i> , <b>2004</b> , 3, 149-58		4
42	Parkinsons Disease-related Circulating microRNA Biomarkers Validation Study. <i>AIMS Medical Science</i> , <b>2015</b> , 2, 7-14	0.4	4
41	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1522-1534	8.9	4
40	Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. <i>Molecular Pharmacology</i> , <b>2019</b> , 96, 862-870	4.3	4
39	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , <b>2019</b> , 2019,	5	4
38	Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 585-597	12.9	4
37	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1409-e140	5.7	4
36	Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009302	5	4
35	IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 26	3.7	3

34	Confident predictability: identifying reliable gene expression patterns for individualized tumor classification using a local minimax kernel algorithm. <i>BMC Medical Genomics</i> , <b>2011</b> , 4, 10	3.7	3
33	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4633-4642	12.9	2
32	Emerging transcriptional landscape and putative therapeutic strategies in young patients with metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14627-e14627	2.2	2
31	Spontaneous Cell Fusions as a Mechanism of Parasexual Recombination in Tumor Cell Populations		2
30	An Assessment of Feature Relevance in Predicting Protein Function from Sequence. <i>Lecture Notes in Computer Science</i> , <b>2004</b> , 52-57	0.9	2
29	Loss of prdm1a accelerates melanoma onset and progression		2
28	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 346-357	6.6	2
27	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2049-2060	6.1	2
26	Deep Learning of Histopathology Images at the Single Cell Level. <i>Frontiers in Artificial Intelligence</i> , <b>2021</b> , 4, 754641	3	2
25	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , <b>2021</b> , 60, 138-150	5	2
24	Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. <i>Communications Biology</i> , <b>2020</b> , 3, 306	6.7	1
23	Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvaa017	0.4	1
22	Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis.. <i>Scientific Reports</i> , <b>2021</b> , 11, 23933	4.9	1
21	Defining the role of RUNX1T1 in "combined" small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20101-e20101	2.2	1
20	iCOSSY: An Online Tool for Context-Specific Subnetwork Discovery from Gene Expression Data. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131656	3.7	1
19	RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15214-e15214	2.2	1
18	Employing gene set top scoring pairs to identify deregulated pathway-signatures in dilated cardiomyopathy from integrated microarray gene expression data. <i>Methods in Molecular Biology</i> , <b>2012</b> , 802, 345-61	1.4	1
17	Novel Human-Derived Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , <b>2021</b> , 99, 435-447	4.3	1

16	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 41	9.8	1
15	Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 561-569	5.2	1
14	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology <b>2013</b> , 187-206		1
13	MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. <i>Journal of Leukocyte Biology</i> , <b>2021</b> , 110, 197-205	6.5	0
12	p63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer.. <i>Nature Communications</i> , <b>2022</b> , 13, 614	17.4	0
11	Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e18541-e18541	2.2	0
10	Expanding the Connectivity Map Concept as the Functional Look-Up Table for Systems Biology. <i>Advances in Molecular Pathology</i> , <b>2019</b> , 2, 201-213	0.3	
9	88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males <b>2021</b> , 9, A96-A96		
8	87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known <b>2021</b> , 9, A95-A95		
7	Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 605-605	2.2	
6	Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3589-3589	2.2	
5	Genomic distinctions between colon and rectal cancer in young patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3574-3574	2.2	
4	The AML Prognostic Marker, AF1q, Is Directly Regulated by MiR-29b.. <i>Blood</i> , <b>2009</b> , 114, 2603-2603	2.2	
3	Genome-Wide shRNA Screen Identifies WEE1 As a Critical Mediator of Cell Fate and Novel Therapeutic Target in AML,. <i>Blood</i> , <b>2011</b> , 118, 3503-3503	2.2	
2	Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, B35-B35 <sup>12.9</sup>		
1	Variant Calling in Next Generation Sequencing Data <b>2021</b> , 129-140		